Methylgene appoints new vice-president of infectious disease

Montreal, QC June 2, 2003 Drug discovery and development company in cancer and infectious diseases, MethylGene, has appointed Dr Nafsika Georgopapadakou as vice-president of infectious disease.

Dr Georgopapadakou was formerly senior director at NewBiotics, a biotech company specializing in anti-infectives and oncolytics in San Diego. Over the past 20 years, she has held positions of increasing responsibility in drug discovery at Bristol-Myers Squibb, Roche and DuPont Pharmaceuticals.

Dr Georgopapadakou is the author or co-author of over 150 research papers, books and abstracts. She is also the founder and editor-in-chief of Drug Resistance Updates, a multidiscipline review journal on anti-microbial and anti-cancer chemotherapy.

She received her BA in Chemistry from Mills College in Oakland, CA, her PhD in biochemistry from Yale University, and had postdoctoral training at Harvard University in Cambridge, Massachusetts.